test
Apeiron Investment Group delivered a letter to the Board of Sensei Biotherapeutics
Market Cap: $41 million| Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer.
On November 2, 2022, Apeiron Investment Group Ltd. (11.2%) delivered an open letter to the Board calling them to take immediate action to regain the trust of shareholders and consolidate shareholder support given the steep and continuous decline in shareholder value and the failure of the company’s sole clinical program. Apeiron also highlighted its significant concerns regarding the chronic underperformance, strategic direction and lack of alignment with shareholders. Apeiron concluded the letter by stating that it continues to believe in the company’s potential and is open to, and hopeful of, finding a constructive resolution to address these concerns. To that end, Apeiron stated that it looks forward to continuing to engage with the Board on these issues for the benefit of all stakeholders